October 31, 2024

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE Prime Market)
Contact person: Takeyoshi Egawa, Vice President,
Senior Manager of Business Administration Department
(TEL. +81-3-6711-5200)

Japan Lifeline Forms Sales Partnership with Terumo for Proprietary Liver Cancer Ablation System

TOKYO, JAPAN – October 31, 2024 – Japan Lifeline Co., Ltd. (TSE: 7575) today announced that it has signed a five-year exclusive distribution agreement with Terumo Corporation ("Terumo") for the proprietary radiofrequency ablation system for liver cancer treatment, "*arfa.*" Under this agreement, Japan Lifeline will supply *arfa* to Terumo, who will handle its sales in Japan.

1. Contract Overview
   (1) Product
   Radiofrequency Ablation System for Liver Cancer Treatment "*arfa*"
   Sales Name: JLL Oncology RFA System
   General Name: Radiofrequency Ablation System
   Medical Device Approval Number: 30100BZX00094000

   (2) Contract Period
   Five years from the start of sales (scheduled for April 2025)

2. Background of the Contract
   Japan Lifeline started working in the gastrointestinal area in 2017 and launched the *arfa*, a radiofrequency ablation system for liver cancer treatment, in 2019. This system uses technology developed in the arrhythmia business. The *arfa* system, as the first domestically produced device of its kind, has gained significant recognition in medical settings and captured about 30% of the domestic market share. Recently, the application of radiofrequency ablation has expanded to tumors beyond liver cancer, prompting Japan Lifeline to pursue this opportunity. Keisuke Suzuki, Japan Lifeline's President and CEO, states, "By entrusting the sales of *arfa* to Terumo, who aim to strengthen their interventional oncology field, our goal is to improve sales efficiency on this business." He further adds, "By the final year of our mid-term business plan, ending March 2028, we aim to achieve a target sales revenue of 3.5 billion yen in the overall gastrointestinal field."

3. Impact on Business Performance
   The contract is expected to have a minor impact on business performance.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.



Liver Cancer Treatment Radiofrequency Ablation System "arfa"